Zotizalkib

CAS No. 2648641-36-3

Zotizalkib( —— )

Catalog No. M37625 CAS No. 2648641-36-3

Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 334 In Stock
5MG 303 In Stock
10MG 487 In Stock
25MG 938 In Stock
50MG 1442 In Stock
100MG 2027 In Stock
200MG 2744 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Zotizalkib
  • Note
    Research use only, not for human use.
  • Brief Description
    Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.
  • Description
    Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). Zotizalkib has strong antitumor activities.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Female SCID/beige mice (5-8 weeks old) bearing Ba/F3 cells Dosage:2 mg/kg, 5 mg/kg, and 10 mg/kg Administration:p.o.; twice a day; for 2 weeks Result:Caused complete tumor regression in ALK mutation-dependent xenograft models.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    ALK
  • Recptor
    ALK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2648641-36-3
  • Formula Weight
    447.41
  • Molecular Formula
    C21H20F3N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 62.5 mg/mL (139.69 mM; Ultrasonic (<80°C)
  • SMILES
    C(F)(F)[C@H]1N2C=3C(=CN4C(N3)=C(C=N4)C(=O)NC(C)(C)COC=5C(C2)=CC(F)=CC5)OC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Brion W Murray, et al. TPX-0131, a Potent CNS-Penetrant, Next-Generation Inhibitor of Wild-Type ALK and ALK-Resistant Mutations. Mol Cancer Ther. 2021 Jun 22;molcanther.0221.2021.?
molnova catalog
related products
  • Tyrphostin AG 879

    Tyrphostin AG 879 effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.

  • Ascrinvacumab

    Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1.

  • CH5424802 analog

    CH5424802 analog is a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.